CACNB3
ENSG00000167535
Target class
Auxiliary transport protein
Chromosome
12
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNB3
- Gene name
- Calcium voltage-gated channel auxiliary subunit beta 3
- Gene symbol
- CACNB3
- Previous gene symbols
- CACNLB3
- Protein name
- Voltage-dependent L-type calcium channel subunit beta-3 (CAB3) (Calcium channel voltage-dependent subunit beta 3)
- Gene biotype
- Protein coding
- Gene family
- Membrane associated guanylate kinases|Calcium voltage-gated channel auxiliary beta subunits
- Target class
- Auxiliary transport protein
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 73.92
- Tissue specificity (Gini)
- 0.447
- Tissue specificity (tau)
- 0.728
- KEGG gene identifiers
- hsa:784
- Protein interaction confidence
- 0.852171
- Protein interaction partners
- 41
- R-HSA-112308
- R-HSA-400042
- R-HSA-419037
- R-HSA-422356
- R-HSA-9856532
- End position
- 48828941
- Start position
- 48813794
- Chromosome
- 12
- Strand
- Forward
- Cytoplasm .
- Golgi apparatus
- Vesicles
Publication evidence
- PubMed 34234349
- Tissue specificity (tau)
- 0.728199
- Expression inequality (Gini)
- 0.446576
Expression in transcripts per million
- Ovary
- 73.92
- Brain - Cerebellar Hemisphere
- 67.19
- Brain - Cerebellum
- 65.58
- Uterus
- 62.56
- Brain - Cortex
- 56.85
Expression in transcripts per million
- Ovary73.92
- Brain - Cerebellar Hemisphere67.19
- Brain - Cerebellum65.58
- Uterus62.56
- Brain - Cortex56.85
- Brain - Frontal Cortex (BA9)52.08
- Cervix - Ectocervix50.09
- Cervix - Endocervix49.58
- Brain - Anterior cingulate cortex (BA24)36.86
- Vagina31.38
- Fallopian Tube31.09
- Brain - Amygdala28.45
- Esophagus - Muscularis25.6
- Artery - Aorta23.43
- Esophagus - Gastroesophageal Junction22.59
- Brain - Caudate (basal ganglia)22.26
- Colon - Sigmoid22.16
- Brain - Nucleus accumbens (basal ganglia)21.74
- Prostate20.46
- Bladder20.36
- Esophagus - Mucosa19.5
- Brain - Hypothalamus18.95
- Brain - Hippocampus18.4
- Nerve - Tibial17.87
- Colon - Transverse17.67
And 29 more, listed on the interactive page.
- GO:0006816
- GO:0070588
- GO:0005737
- GO:0005829
- GO:0005891
- GO:0016020
- GO:0005245
- GO:0005515
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (11)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker